Luteolin, ellagic acid and punicic acid are natural products that inhibit prostate cancer metastasis

Carcinogenesis

Volumn 35, Issue 10, 2014, Pages 2321-2330

  Wang, Lei ^a   Li, Wenfang ^a   Lin, Muqing ^b   Garcia, Monika ^a   Mulholland, David ^c   Lilly, Michael ^d   Martins Green, Manuela ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Shenzhen University   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIMETASTATIC AGENT; CHEMOKINE RECEPTOR CXCR4; ELLAGIC ACID; HERBACEOUS AGENT; INTERLEUKIN 8; K RAS PROTEIN; LUTEOLIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PUNICIC ACID; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT; BIOLOGICAL PRODUCT; CXCL12 PROTEIN, MOUSE; CXCR4 PROTEIN, MOUSE; LINOLENIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; CANCER GROWTH; CANCER INHIBITION; CELL ADHESION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS INHIBITION; MIGRATION INHIBITION; MOUSE; NONHUMAN; POMEGRANATE JUICE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; SCID MOUSE; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; DRUG EFFECTS; DRUG SCREENING; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PROSTATIC NEOPLASMS; VASCULAR ENDOTHELIUM;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL PRODUCTS; CHEMOKINE CXCL12; ELLAGIC ACID; ENDOTHELIUM, VASCULAR; HUMANS; LINOLENIC ACIDS; LUTEOLIN; MALE; MICE; MICE, INBRED C57BL; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84906839766     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu145     Document Type: Article

References (47)

1. American Cancer Society. http://www.cancer.org/(15 December 2013, date last accessed).
2. Bubendorf, L. et al. (2000) Metastatic patterns of prostate cancer: an autopsy study of 1, 589 patients. Hum. Pathol., 31, 578-583.
3. Higano, C.S. et al. (2010) Sipuleucel-T. Nat. Rev. Drug Discov., 9, 513-514.
4. Scher, H.I. et al. (2010) Antitumour activity of MDV3100 in castrationresistant prostate cancer: a phase 1-2 study. Lancet, 375, 1437-1446.
5. Sartor, O. et al. (2013) Abiraterone and its place in the treatment of metastatic CRPC. Nat. Rev. Clin. Oncol., 10, 6-8.
6. Pal, S.K. et al. (2013) Enzalutamide for the treatment of prostate cancer. Expert Opin. Pharmacother., 14, 679-685.
7. Ryan, C.J. et al. (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med., 368, 138-148.
8. Stein, M.N. et al. (2012) Abiraterone in prostate cancer: a new angle to an old problem. Clin. Cancer Res., 18, 1848-1854.
9. Yakes, F.M. et al. (2011) Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol. Cancer Ther., 10, 2298-2308.
10. Smith, D.C. et al. (2013) Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J. Clin. Oncol., 31, 412-419.
11. Albrecht, M. et al. (2004) Pomegranate extracts potently suppress proliferation, xenograft growth, and invasion of human prostate cancer cells. J. Med. Food, 7, 274-283.
12. Syed, D.N. et al. (2008) Dietary agents for chemoprevention of prostate cancer. Cancer Lett., 265, 167-176.
13. Rettig, M.B. et al. (2008) Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-kappa B-dependent mechanism. Mol. Cancer Ther., 7, 2662-2671.
14. Malik, A. et al. (2005) Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc. Nat. Acad. Sci. USA, 102, 14813-14818.
15. Pantuck, A.J. et al. (2006) Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin. Cancer Res., 12, 4018-4026.
16. Paller, C.J. et al. (2013) A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer. Prostate Cancer Prostatic Dis., 16, 50-55.
17. Wang, L. et al. (2011) Cellular and molecular mechanisms of pomegranate juice-induced anti-metastatic effect on prostate cancer cells. Integr. Biol. (Camb)., 3, 742-754.
18. Gil, M.I. et al. (2000) Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. J. Agric. Food Chem., 48, 4581-4589.
19. El Kar, C. et al. (2011) Pomegranate (Punica granatum) juices: chemical composition, micronutrient cations, and antioxidant capacity. J. Food Sci., 76, C795-C800.
20. Hora, J.J. et al. (2003) Chemopreventive effects of pomegranate seed oil on skin tumor development in CD1 mice. J Med. Food, 6, 157-161.
21. Lansky, E.P. et al. (2005) Pomegranate (Punica granatum) pure chemicals show possible synergistic inhibition of human PC-3 prostate cancer cell invasion across Matrigel. Invest. New Drugs, 23, 121-122.
22. Zhou, Q. et al. (2009) Luteolin inhibits invasion of prostate cancer PC3 cells through E-cadherin. Mol. Cancer Ther., 8, 1684-1691.
23. Gasmi, J. et al. (2010) Growth inhibitory, antiandrogenic, and pro-apoptotic effects of punicic acid in LNCaP human prostate cancer cells. J Agric. Food Chem., 58, 12149-12156.
24. Wang, L. et al. (2012) Specific pomegranate juice components as potential inhibitors of prostate cancer metastasis. Transl. Oncol., 5, 344-355.
25. Rocha, A. et al. (2012) Pomegranate juice and specific components inhibit cell and molecular processes critical for metastasis of breast cancer. Breast Cancer Res. Treat., 136, 647-658.
26. Euhus, D.M. et al. (1986) Tumor measurement in the nude mouse. J. Surg. Oncol., 31, 229-234.
27. Mulholland, D.J. et al. (2012) Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res., 72, 1878-1889.
28. Jo, H. et al. (2012) Small molecule-induced cytosolic activation of protein kinase Akt rescues ischemia-elicited neuronal death. Proc. Nat. Acad. Sci. USA, 109, 10581-10586.
29. Petreaca, M.L. et al. (2007) Transactivation of vascular endothelial growth factor receptor-2 by interleukin-8 (IL-8/CXCL8) is required for IL-8/CXCL8-induced endothelial permeability. Mol. Biol. Cell, 18, 5014-5023.
30. Marshall, C.J. (1995) Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell, 80, 179-185.
31. Seeram, N.P. et al. (2007) Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland. J. Agric. Food Chem., 55, 7732-7737.
32. González-Sarrías, A. et al. (2010) Occurrence of urolithins, gut microbiota ellagic acid metabolites and proliferation markers expression response in the human prostate gland upon consumption of walnuts and pomegranate juice. Mol. Nutr. Food Res., 54, 311-322.
33. Vicinanza, R. et al. (2013) Pomegranate juice metabolites, ellagic acid and urolithin a, synergistically inhibit androgen-independent prostate cancer cell growth via distinct effects on cell cycle control and apoptosis. Evid. Based. Complement. Alternat. Med., 2013, 247504.
34. Carmeliet, P. et al. (2000) Angiogenesis in cancer and other diseases. Nature (London), 407, 249-257.
35. Weis, S.M. et al. (2011) Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med., 17, 1359-1370.
36. Aragon-Ching, J.B. et al. (2008) The role of angiogenesis inhibitors in prostate cancer. Cancer J., 14, 20-25.
37. Sartippour, M.R. et al. (2008) Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo. Int. J. Oncol., 32, 475-480.
38. Jahroudi, N. et al. (1995) The role of endothelial cells in tumor invasion and metastasis. J. Neurooncol., 23, 99-108.
39. Vestweber, D. et al. (2009) Cell adhesion dynamics at endothelial junctions: VE-cadherin as a major player. Trends Cell Biol., 19, 8-15.
40. Wels, J. et al. (2008) Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev., 22, 559-574.
41. Ahmad, S.A. et al. (2002) The role of the microenvironment and intercellular cross-talk in tumor angiogenesis. Semin. Cancer Biol., 12, 105-112.
42. Waugh, D.J. et al. (2008) The interleukin-8 pathway in cancer. Clin. Cancer Res., 14, 6735-6741.
43. Lai, Y. et al. (2011) Interleukin-8 induces the endothelial cell migration through the activation of phosphoinositide 3-kinase-Rac1/RhoA pathway. Int. J. Biol. Sci., 7, 782-791.
44. Taichman, R.S. et al. (2002) Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res., 62, 1832-1837.
45. Zlotnik, A. et al. (2011) Homeostatic chemokine receptors and organ-specific metastasis. Nat. Rev. Immunol., 11, 597-606.
46. Huang, E.H. et al. (2009) A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J. Surg. Res., 155, 231-236.
47. Tan, W. et al. (2006) The Galpha13-Rho signaling axis is required for SDF-1-induced migration through CXCR4. J. Biol. Chem., 281, 39542-39549.